AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE IB STUDY WITH EXPANSION COHORTS TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND THERAPEUTIC ACTIVITY OF RO7009789 (CD40 AGONISTIC MONOCLONAL ANTIBODY) OR BEVACIZUMAB (ANTI-VEGF MONOCLONAL ANTIBODY, PART II) IN COMBINATION WITH VANUCIZUMAB (ANTI-ANG2 AND ANTI-VEGF BI-SPECIFIC MONOCLONAL ANTIBODY) IN PATIENTS WITH METASTATIC SOLID TUMORS

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2015
This article has no abstract
Epistemonikos ID: 7540e59eaaa3d7d16560b220c318599d7b611ccf
First added on: Apr 16, 2025